Literature DB >> 16552181

Focal adhesion kinase signaling and the aggressive melanoma phenotype.

Angela R Hess1, Mary J C Hendrix.   

Abstract

Focal adhesion kinase (FAK) mediates myriad cellular functions and has been found to be overexpressed in numerous human cancers. We recently explored the role of FAK in promoting the aggressive phenotype of melanoma cells, characterized by increased invasion, migration, and vasculogenic mimicry (VM) potential. We found FAK to be phosphorylated on its key tyrosine residues (397 and 576) in aggressive melanoma cells cultured on a three-dimensional type 1 collagen matrix in vitro, as well as in radial and vertical growth phase melanomas in situ. Furthermore, expressing FAK-related non-kinase (FRNK) in melanoma cells directly resulted in the inhibition of the aggressive phenotype, as demonstrated by decreased invasion, migration and VM potential, in part by blocking an Erk1/2 mediated signaling pathway. Additional data indicated that increased FAK activity may promote cellular proliferation and anchorage independent growth of aggressive melanoma. Together these observations implicate FAK as a promoter of the aggressive melanoma phenotype, thereby identifying a rational target for therapeutic intervention of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552181     DOI: 10.4161/cc.5.5.2518

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  19 in total

Review 1.  Mig-7 linked to vasculogenic mimicry.

Authors:  Gavin P Robertson
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

2.  TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements.

Authors:  Mary F Walsh; Dinakar R Ampasala; Arun K Rishi; Marc D Basson
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 3.  Cells move when ions and water flow.

Authors:  Albrecht Schwab; Volodymyr Nechyporuk-Zloy; Anke Fabian; Christian Stock
Journal:  Pflugers Arch       Date:  2006-10-05       Impact factor: 3.657

4.  Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.

Authors:  Jinming Yang; Wei-Hua Pan; Gary A Clawson; Ann Richmond
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

5.  Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.

Authors:  Yue-Zu Fan; Wei Sun
Journal:  World J Gastrointest Surg       Date:  2010-04-27

Review 6.  Focal adhesion kinase as a cancer therapy target.

Authors:  Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

Review 7.  Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.

Authors:  Xiaoxu Wei; Yunhua Chen; Xianjie Jiang; Miao Peng; Yiduo Liu; Yongzhen Mo; Daixi Ren; Yuze Hua; Boyao Yu; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

8.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Authors:  Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Authors:  Alexandra A Mourad-Zeidan; Vladislava O Melnikova; Hua Wang; Avraham Raz; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

Review 10.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu
Journal:  Pharmacol Ther       Date:  2016-01-22       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.